Posters & Publications

2022 Fall Clinical Dermatology Conference - October 2022

Atopic Dermatitis Unmet Need and Prescribing Trends

2022 Fall Clinical Dermatology Conference - October 2022

Psoriasis Unmet Need & Prescribing Trends

5CC World Congress - September 2022

Treatment of psoriasis via the small intestine

5CC World Congress - September 2022

Extracellular Vesicles for the Treatment of Inflammatory Skin Diseases

2022 European Academy of Dermatology and Venereology (EADV) Congress - September 2022

Biomarker Evidence of Anti-Inflammatory Effects of EDP1815 in a Phase 2 Psoriasis Clinical Trial

Society for Mucosal Immunology (ICMI) - July 2022

Orally-dosed Prevotella histicola, EDP1815, induces a population of CD4+ T cells that can mediate resolution of inflammation

105th Annual American Association of Immunology - May 2022

Treatment with an orally delivered non-replicating, non-colonizing strain of Veillonella parvula resolves systemic inflammation

Late-Breaking Oral Abstract, 2022 American Academy of Dermatology (AAD) Annual Meeting - March 2022

A phase 2 study investigating the effect of EDP1815, an orally-delivered, anti-inflammatory, gut-restricted commensal microbe in the treatment of mild and moderate plaque psoriasis

Winter Clinical Dermatology Congress - January 2022

Mechanism and Proof of Concept in Psoriasis

European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) - October 2021

Oral Delivery of Non-live Preparation of Veillonella parvula Modulates CNS Inflammation via the Small Intestinal Axis: a Novel Approach to Treating Neuroinflammatory Diseases

Virtual IMMUNOLOGY2021, the 104th Annual Meeting of the American Association of Immunologists (AAI) - May 2021

Orally Delivered Microbial Extracellular Vesicles Modulate Systemic Inflammation Through the Small Intestinal Axis (SINTAX

Society for Mucosal Immunology Virtual Congress - January 2021

Immune Mechanisms of the Systemic Effects of EDP1815: An Orally Delivered, Gut-Restricted Microbial Drug Candidate for the Treatment of Inflammatory Diseases

San Antonio Breast Cancer Symposium^® - December 2020

A phase I/II clinical trial of EDP1503 with pembrolizumab for triple-negative breast cancer

Society for Immunotherapy of Cancer’s (SITC) Annual Meeting Congress - November 2020

Oral delivery of a microbial extracellular vesicle induces potent anti-tumor immunity in mice

European Academy of Dermatology and Venereology (EADV) Meeting - October 2020

Orally-administered EDP1815, a single strain of Prevotella histicola, has potent systemic anti-inflammatory effects in Type 1, Type 2, and Type 3 inflammatory models

ESMO World Congress on Gastrointestinal Cancer Meeting - July 2020

EDP1503 induces antitumor responses via gut-mediated activation of both innate and adaptive immunity

American Academy of Dermatology (AAD) - June 2020

Orally-administered EDP1815, a monoclonal strain of Prevotella histicola, has potent systemic anti-inflammatory effects

British Society of Immunology - December 2019

Orally-administered EDP1815, a monoclonal strain of Prevotella histicola, has potent systemic anti-inflammatory effects without systemic exposure in mice and psoriasis patients

Society for Immunotherapy of Cancer’s (SITC) Annual Meeting Congress - November 2019

Monoclonal microbial EDP1503 induces antitumor responses via gut-mediated activation of both innate and adaptive immunity